Randomized Phase III Study of Amifostine in Patients Treated with Chemoradiation for Inoperable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
William Levin, MD
University of Pennsylvania Cancer Center
Last Modified: November 4, 2001
Presenter: R. Komaki
Affiliation: Radiation Oncology, University of Texas M. D. Anderson Cancer Center,
The radioprotective property of thiol-containing compounds has been
well known for some time. Amifostine(WR-2721) is the most well known of
these agents. The proposed mechanism of action is the scavenging of
radiation-induced free radicals.
A prospective randomized study was conducted to determine
whether amifostine reduces the rate of severe esophagitis, hematologic, and
pulmonary toxicities associated with concurrent chemoradiation and/or
improves the survival of patients with inoperable NSCLC.
Materials and Methods
- 62 patients with inoperable stage II or III NSCLC were entered onto this
single institution randomized study.
- They were treated by thoracic radiation therapy (TRT) with 1.2 Gy/Fx,
bid to a total dose of 69.6 Gy and oral VP-16 and cisplatin
- Amifostine (500 mg i.v. twice weekly) was given before chemoradiation
(Arm 1); the control group received chemoradiation without amifostine (Arm
- Thirty-one patients were enrolled in each arm with a median follow-up
of 6 months.
- Patient and tumor characteristics were equally distributed in both
- Complete response (CR) occurred in 11 of the 31 patients who received
amifostine (35%) and in 6 of the 31 patients (19%) who did not (p=
- Median survival time has not yet been reached on arm 1; it was 20
months on arm 2.
- Severe acute esophagitis ( grade 3) was 6.5% in Arm 1
compared to 26%in Arm 2 (p=0.038).
- Acute pneumonitis ( grade 3) was 3.2% in Arm 1 compared to 19%
in Arm 2 (p = 0.045).
- There was no significant difference in hematologic toxicities between
the two arms. Hypotension (20 mm Hg decrease from baseline BP) was
significantly more frequent in Arm 1 65% vs 3.0% in Arm 2 (p=0.00001).
- Only one patient discontinued the treatment because of a hypotensive
- Amifostine significantly reduced acute pneumonitis and severe acute
esophagitis although it caused significantly more hypotensive episodes.
- Further follow-up is needed to evaluate the long-term effects in late
reacting normal tissues as well as survival.
- One of major implications of this study is that more rigorous cancer
regimens, such as those utilizing chemoirradiation, might be employed if
integrity of normal tissue could be preserved.
- Of course, when discussing radioprotectants, one must always be aware
of the theoretical concern of tumor protection.
- Another interesting area of active research is the use of subcutaneous
amifostine, which offers a more convenient method of delivery than the
i.v. form, and may have a better side-effect profile.
Gefitinib Outperforms Combo Therapy in Lung Cancer Trial
Jan 25, 2015 - In a phase III clinical trial, gefitinib was superior to carboplatin-paclitaxel in extending survival for patients with non-small-cell lung cancer, particularly those patients with epidermal growth factor receptor gene mutations, according to a study published online Aug. 19 in the New England Journal of Medicine.
Frequently Asked Questions
National Cancer Institute
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!